R & D

Selecting innovative drug targets to build a pipeline of development programs


Focusing on small molecule drug discovery, Proximagen selects innovative drug targets to build a pipeline of development programs, each with the potential to provide a significant advance in the treatment of disease where there remains significant unmet medical need, including:

  • Central Nervous System (CNS) disorders, such as cognitive impairment and epilepsy
  • Chronic pain
  • Inflammation

To quickly and efficiently optimize new potential candidate drugs (CDs), we have in-house capabilities for each of these key disciplines needed for small molecule drug discovery, enabling close interaction and rapid decision-making:

  • Medicinal chemistry
  • Biology
  • Drug metabolism and pharmacokinetics (DMPK)

We also have teams of experienced individuals providing expertise in the areas of:

  • Preclinical development
  • Early clinical development and translational medicine